Chi­na and US con­sid­er pos­si­ble so­lu­tion for US-list­ed com­pa­nies in vi­o­la­tion of new law — re­port

As sev­er­al US-list­ed Chi­nese biotechs rush to com­ply with a new law or face the threat of delist­ing, the two coun­tries are re­port­ed­ly work­ing out a deal to re­solve the is­sue by al­low­ing Amer­i­can reg­u­la­tors to re­view au­dit re­ports in Hong Kong, ac­cord­ing to the Wall Street Jour­nal.

BeiGene, Hutchmed, Zai Lab, I-Mab, Sino­vac, Gra­cell Biotech­nolo­gies, Ada­gene and Burn­ing Rock Biotech have all been sin­gled out by the SEC un­der the Hold­ing For­eign Com­pa­nies Ac­count­able Act, which calls for the delist­ing of any for­eign com­pa­nies au­dit­ed by a firm that the Pub­lic Com­pa­ny Ac­count­ing Over­sight Board is un­able to re­view for three con­sec­u­tive years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER